Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions

Table 3 Clinical trials in patients with oligometastatic non-small cell lung cancer

Clinical trial identifier	Title	Objective
NCT01185639	Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-Small Cell Lung Cancer	To evaluate the efficacy of SBRT in oligometastatic NSCLC patients who achieve partial response or stable disease after 4 cycles of ChT. The hypothesis is that SBRT after 4 cycles of ChT is feasible, safe, with good local control, and improves time to progression
NCT 02314364	A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC	To evaluate SBRT in patients with stage 4 NSCLC and EGFR, ALK, or ROS1 mutations who have been treated with erlotinib, gefitinib, or other targeted drugs
NCT03275597	Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition	To evaluate the safety and tolerability of SBRT combined with durvalumab and tremelimumab for oligometastatic NSCLC
NCT02975609	Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer	To compare the efficacy and safety of SBRT vs conventional radiotherapy after response to 4-6 cycles of chemotherapy. Outcome measures for both groups include PFS, OS, and adverse effects
NCT03808337	Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease	To determine if SBRT to all oligometastatic lesions can extend time to progression
NCT02417662	Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer (SARON)	Phase III study of efficacy and safety in oligometastatic NSCLC patients comparing conventional ChT alone to ChT plus conventional radiotherapy to the primary tumor and SBRT to the metastases

SBRT: Stereotactic body radiation therapy; NSCLC: Non-small cell lung cancer; ChT: Chemotherapy; PFS: Progression-free survival; OS: Overall survival.